Earnings ·
Immuron Limited reported FY2026 global sales revenue of A$7.7 million, a 6% increase year-over-year, with growth in…
IMRNImmuron Ltd
Immuron Limited reported FY2026 global sales revenue of A$7.7 million, a 6% increase year-over-year, with growth in Australia (up 10%) and the U.S. (up 7%). The company has shifted to a strategic partnering model for its clinical assets, IMM-124E and IMM-529, to reduce R&D expenses and cash burn. IMM-529 has received FDA IND approval for Phase 2 trials for Clostridioides difficile infection, while IMM-124E is eligible for an end-of-Phase 2 meeting with the FDA. As of December 31, 2025, the company held A$10.0 million in cash. Immuron is an Australian biopharmaceutical company developing orally delivered targeted polyclonal antibodies for infectious diseases.